Clinical examinations were performed for all participants in both MDC and MOS. Body-mass Index (BMI) was defined as the weight divided by the squared height (kg/m2). Systolic and diastolic blood pressure (mmHg) were measured using the mercury-column sphygmomanometer. Analyses of fasting glucose, High-density Lipoprotein (HDL) and triglycerides were carried out using routine standards methods at the Department of Clinical Chemistry, Malmö. Low-density Lipoprotein (LDL) was calculated using the Friedwald equation. Insulin levels measurements were performed using Mercodia Insulin ELISA (Mercodia, Uppsala, Sweden).
Type 2 Diabetes (T2D) was defined as a fasting plasma glucose > 7 mmol/L or a history of physician diagnosis of T2D or being on antidiabetic medication or having been registered in local or Swedish diabetes registries [18 (link)] and Coronary Artery Disease (CAD) as myocardial infarction (fatal and non-fatal), death due to ischemic heart diseases or coronary revascularization as described previously [19 (link), 20 (link)].
Type 2 Diabetes (T2D) was defined as a fasting plasma glucose > 7 mmol/L or a history of physician diagnosis of T2D or being on antidiabetic medication or having been registered in local or Swedish diabetes registries [18 (link)] and Coronary Artery Disease (CAD) as myocardial infarction (fatal and non-fatal), death due to ischemic heart diseases or coronary revascularization as described previously [19 (link), 20 (link)].
Free full text: Click here
